## Highlights of This Issue 6367

### SPECIAL FEATURES

#### CCR Translations

- **Therapeutic Oligonucleotides: The Road Not Taken**
  Cy A. Stein and Sanjay Goel
  See commentary p. 6582

#### Molecular Pathways

- **The Role of Erythropoietin and Erythropoiesis-Stimulating Agents in Tumor Progression**
  Benjamin D. Hedley, Alison L. Allan, and Anargyros Xenocostas

- **TLX1-Induced T-cell Acute Lymphoblastic Leukemia**
  Kim De Keersmaecker and Adolfo A. Ferrando

#### CCR Focus

- **Antibody Conjugates: The Future Is Now**
  Susan E. Bates

- **Antibody Conjugate Therapeutics: Challenges and Potential**
  Beverly A. Teicher and Ravi V.J. Chari

- **Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox**
  Robert J. Kreitman and Ira Pastan

- **Antibody-Radiouclide Conjugates for Cancer Therapy: Historical Considerations and New Trends**
  Martina Steiner and Dario Neri

- **Antibody-Drug Conjugates of Calicheamicin Derivative: Gentuzumab Ozogamicin and Inotuzumab Ozogamicin**
  Alejandro D. Ricart

- **Brentuximab Vedotin (SGN-35)**
  Jessica Katz, John E. Janik, and Anas Younes

### Review

- **Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC**
  René H. Medema, Chia-Chi Lin, and James Chih-Hsin Yang

### CANCER THERAPY: PRECLINICAL

- **Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism**
  Christopher G. Twitty, Shawn M. Jensen, Hong-Ming Hu, and Bernard A. Fox

- **Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer**
  Ning Jin, Tianyun Jiang, David M. Rosen, Barry D. Nelkin, and Douglas W. Ball

- **The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to Sites of DNA Damage, Suppressing Repair of DNA Double-Strand Breaks and Enhancing Radiosensitization**
6500  Significant Biological Role of Sp1 Transactivation in Multiple Myeloma

6510  Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells

6522  EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies
Virginie Poindeissou, Djamila Ouaret, Karima El Ouadrani, Aude Battistella, Virginie F. Boudou, Sylvia Dumont, Pascale Cervera, Jean-Francois Pefou, Thierry Andre, Christophe Tournigand, Benoist Chibaudel, Aimery de Gramont, and Annette K. Larsen

6531  Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
Roberta Rosa, Davide Melisi, Vincenzo Damiano, Roberto Bianco, Sonia Garofalo, Teresa Gelardi, Sudhir Agrawal, Federica Di Nicolantonio, Aldo Scarpa, Alberto Bardelli, and Giampaolo Tortora

6542  High XRCC1 Protein Expression Is Associated with Poorer Survival in Patients with Head and Neck Squamous Cell Carcinoma

6553  Discriminant Analysis of 18F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma
Mirwais Wardak, Christiaan Schippers, Magnus Dahlbom, Timothy Cloughesy, Wei Chen, Nagiccttiar Satyamurthy, Johannes Cernin, Michael E. Phelps, and Sung-Cheng Huang

6563  PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients
Tamara L. Lotan, Bora Gurel, Siobhan Sutcliffe, David Esopi, Wenman Liu, Junfeng Xu, Jessica L. Hicks, Ben H. Park, Elizabeth Humphreys, Alan W. Partin, Misop Han, George J. Netto, William B. Isaacs, and Angelo M. De Marzo

6574  Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin
Ahmad A. Tarhini, Paul Frankel, Kim A. Margolin, Scott Christensen, Christopher Ruel, Janice Shippe-Spotloe, David R. Gandara, Alice Chen, and John M. Kirkwood

6582  A Phase I Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

See article p. 6369

The Journal of Clinical and Translational Research v www.aacrjournals.org

The Journal of Clinical and Translational Research v www.aacrjournals.org

IMAGING, DIAGNOSIS, PROGNOSIS

6500  Significant Biological Role of Sp1 Transactivation in Multiple Myeloma

6510  Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells

6522  EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies
Virginie Poindeissou, Djamila Ouaret, Karima El Ouadrani, Aude Battistella, Virginie F. Boudou, Sylvia Dumont, Pascale Cervera, Jean-Francois Pefou, Thierry Andre, Christophe Tournigand, Benoist Chibaudel, Aimery de Gramont, and Annette K. Larsen

6531  Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
Roberta Rosa, Davide Melisi, Vincenzo Damiano, Roberto Bianco, Sonia Garofalo, Teresa Gelardi, Sudhir Agrawal, Federica Di Nicolantonio, Aldo Scarpa, Alberto Bardelli, and Giampaolo Tortora

6542  High XRCC1 Protein Expression Is Associated with Poorer Survival in Patients with Head and Neck Squamous Cell Carcinoma

6553  Discriminant Analysis of 18F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma
Mirwais Wardak, Christiaan Schippers, Magnus Dahlbom, Timothy Cloughesy, Wei Chen, Nagiccttiar Satyamurthy, Johannes Cernin, Michael E. Phelps, and Sung-Cheng Huang

6563  PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients
Tamara L. Lotan, Bora Gurel, Siobhan Sutcliffe, David Esopi, Wenman Liu, Junfeng Xu, Jessica L. Hicks, Ben H. Park, Elizabeth Humphreys, Alan W. Partin, Misop Han, George J. Netto, William B. Isaacs, and Angelo M. De Marzo

6574  Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin
Ahmad A. Tarhini, Paul Frankel, Kim A. Margolin, Scott Christensen, Christopher Ruel, Janice Shippe-Spotloe, David R. Gandara, Alice Chen, and John M. Kirkwood

6582  A Phase I Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

See article p. 6369

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

6592  Comparison of Continuous versus Categorical Tumor Measurement-Based Metrics to Predict Overall Survival in Cancer Treatment Trials
Ming-Wen An, Sumithra J. Mandrekar, Megan E. Branda, Shuna L. Hillman, Alex A. Adjei, Henry C. Pitot, Richard M. Goldberg, and Daniel J. Sargent

See article p. 6369

The Journal of Clinical and Translational Research v www.aacrjournals.org

The Journal of Clinical and Translational Research v www.aacrjournals.org
LETTERS TO THE EDITOR

KRAS rs61764370 in Epithelial Ovarian Cancer—Letter
Joanne B. Weidhaas and Frank J. Slack

KRAS rs61764370 in Epithelial Ovarian Cancer—Response
Harvey A. Risch, Andrew Berchuck, and Paul D.P. Pharoah; for the Ovarian Cancer Association Consortium

ABOUT THE COVER

The work by Poindessous and colleagues shows that inhibition of EGFR- and VEGF(R)-signaling by combinations of two small molecule tyrosine kinase inhibitors (TKI), afatinib and vargatelf, has synergistic activity in colorectal cancer models that are refractory to combinations of the monoclonal antibodies cetuximab and bevacizumab. Importantly, only the TKIs were able to attenuate the phosphorylation of intracellular EGFR- and VEGFR-receptors which was accompanied by the induction of apoptotic cell death as indicated by TUNEL staining (nuclear DNA in blue, apoptotic nuclei in white). This work provides a rationale for clinical trials of the afatinib and vargatelf combination, even in patients with mutant KRAS. For details, see the article by Poindessous and colleagues on page 6522 of this issue.
Clinical Cancer Research

17 (20)


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://clincancerres.aacrjournals.org/content/17/20">http://clincancerres.aacrjournals.org/content/17/20</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>